Factors Causing Acinetobacter Baumannii Resistance to Carbapenem Antibiotics in Patients with Healthcare Associated Infection (HCAI) at Dr. Moewardi Hospital, Surakarta

Widana Primaningtyas, Eti Poncorini Pamungkasari, Sugiarto -


Background: Acinetobacterbaumannii is a negative gram opportunistic bacteriumhaving high survival ability in the environment. Carbapenem is a drug of choice for infections caused by Acinetobacterbaumannii, which in the last decade prevalence of Carbapenem Resistant Acinetobacterbaumannii (CRAB) has increased. CRAB is commonly found in a nosocomial infection case and even into disease outbreak and epidemics in various hospitals. However, CRAB in community-associated infection data is still limited primarily in Indonesia. Therefore the researchers intend to do study factors causing CRAB in hospital and community setting in patients with Healthcare Associated Infection (HCAI).

Subjects and Method: This study was an observational analytic study, with case control design. The study was conducted in RS Dr. Moewardi Surakarta in March-August 2017. Taking subject used fixed disease sampling method with the number of samples were 104 subjects. The dependent variable was the incidence of Acinetobacterbaumannii resistance to carbapenem antibiotics in HCAI patients. Independent variables were history of antibiotic use, patient functional status, intensive unit maintenance and comorbid conditions. Dependent and independent variables were measured by using a questionnairechecklist and then analyzed by using multiple logistic regression analysis.

Results: Previous antibiotic conformity history (OR = 0.12; 95% CI = 0.03 to 0.45; p = 0.002) and the patient functional status (OR = 6.72; 95% CI = 2.08 to 21.68; p = 0.001) increased risk of resistance of Acinetobacterbaumannii to carbapenem (CRAB) in Healthcare-Associated Infections (HCAI) patients and was statistically significant. Treatment at intensive unit (OR = 0.76; 95% CI = 0.26 to 2.23; p = 0.613) and comorbid conditions (OR = 0.38; 95% CI = 0.12 to 1.23; p = 0.106) increased risk of Acinetobacterbaumannii resistance to carbapenem (CRAB) in Healthcare Associated Infections (HCAI) patients although it was statistically insignificant.

Conclusion:Previous antibiotic conformity history and functional status of patients are a factor affecting Acinetobacterbaumannii resistance to carbapenem (CRAB) in Healthcare-Associated Infections (HCAI) patients.

Keyword: Acinetobacterbaumannii, carbapenem, healthcare associated infection.

CorrespondenceWidana Primaningtyas. Master Program in Public Health, Sebelas Maret University, Jl. Ir. Sutami 36 A, Surakarta 57126, Central Java. Email: Mobile: +6285229035800.

Indonesian Journal of Medicine (2017), 2(2): 125-138

Full Text:



Abernethy AP, Shelby James T, Fazekas BS, Woods D, dan Currow DC (2005). The Australia modified Karnofsky Performance Status (AKPS) Scale: a Revised Scale for Contemporary Palliative Care Clinical Practice [ISRCTN81117481]. BMC Palliative Care, 4(7).

AdibhesamiH, Masoumeh D, Hojjat Z, Fariba B, Mohammad R, Mohammad RP, Mahboobeh ST, Aliramezani A, dan Ghourchian S (2016). Carbapenem Resistant Acinetobacter baumannii Recovered from Burn Patients. Journal of Pharmacy and Pharmaceutical Sciences, 19(3): 339 – 348.

Apostolopoulou E, Raftopoulos V, Terzis K, Elefsiniotis I (2010).Infection Probability Score, APACHE II and KARNOFSKY Scoring Systems as Predictors of Bloodstream Infection Onset in Hematology-Oncology Patients. BMC Infectious Disease, 10: 135-143.

Arvaniti K, Lathyris D, Ruimy R, Haidich AB, Koulourida V, Nikolaidis P, Matamis D dan Miyakis S (2012). The Importance of Colonization Pressure in Multiresistant Acinetobacter bau-mannii Acquisition in a Greek Intensive Care Unit. Critical Care, 16 (R102): 1-11.

Ballouz T, Aridi J, Afif C, Irani J, Lakis C, Nasreddine R, dan Azar E (2017). Risk Factors, Clinical Presentation, and Outcome of Acinetobacter baumannii Bacteremia. Frontiers in Cellular and Infection Microbiology, 7(156): 1-8.

Bialvaei ZA, Kouhsari E, Salehi Abargouei A, Amirmozafari N, Ramazanzadeh R, Ghadimi Daresajini A, dan Sedighi M (2017). Epidemiology of multidrug resistant Acinetobacter baumannii strains in Iran: a systematic review and metaanalysis. Journal of Chemotherapy, 1-11.

Camp C, dan Tatum OL (2010). A Review of Acinetobacter baumannii as a highly successful pathogen in times of war. Lab Medicine, 41(11): 649-657.

Cardoso T, Almeida M, Friedman D, Aragao I, Costa Pereira A, Sarmento AE, dan Azevedp L (2014). Classification of Healthcare Associated Infection: a Systematic Review 10 Years After The First Proposal. Biomed Central Medicine, 12(40): 1-13.

CardosoT, Ribeiro O, Araga IC, Costa Pereira A, dan Sarmento AE (2012). Additional Risk Factors for Infection by Multidrug Resistant Pathogens in Healthcare Associated Infection: a Large Cohort Study. BMC Infectious Diseases, 12(375).

Carey EC, Covinsky KE, Lui LY, Eng C, Sands LP, and Walter LC (2008). Prediction of Mortality in Community Living Frail Elderly People with Long Term Care Needs. Journal of the American Geriatrics Society, 56 (1): 68-75.

Chang HH, Cohen T, Grad YH, Hanage WP, O’Brien TF, dan Lipsitch M (2015). Origin and Proliferation of Multiple Drug Resistance in Bacterial Pathogens. Microbiology and Molecular Biology Reviews, 79(1): 101-116.

Cheon S, Kim MJ, Yun SJ, Moon JY dan Kim YS (2016). Controlling endemic multidrug resistant Acinetobacter baumannii in Intensive Care Units using antimicrobial stewardship and infection control. Korean Journal International Medicine, 31: 367-374.

Chopra T, Marchaim D, Awali RA, Krishna A, Johnson P, Tansek R, Chaudary K, Lephart P, et al. (2013). Epidemiology of Bloodstream Infections Caused by Acinetobacter baumannii and Impact of Drug Resistance to both Carbapenems and Ampicillin Sulbactam on Clinical Outcomes. Antimicrobial Agents and Chemotherapy, 57(12):. 6270-6275.

Chopra T, Marchaim D, Johnson PC, Awali RA, Doshi H, Chalana I, Davis N, Zhao JJ, et al. (2014). Risk Factors and Outcomes for Patients with Bloodstream Infection Due to Acinetobacter baumannii calcoaceticus Complex. Antimicrobial Agents and Chemotherapy, 58(8): 4630-4635.

Dijkshoorn L, Nemec A, Seifert H (2007). An increasing threat in hospitals: multidrug resistant Acinetobacter baumannii. Nature Reviews Microbiology, 5: 939-951.

Duijn PJV dan Bonten MJM (2014). Antibiotic rotation strategies to reduceantimicrobial resistance in Gramnegative bacteria in European intensive care units: study protocol for a cluster randomized crossover controlled trial. Trials, 15: 277-285.

Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, dan Scheetz MH (2011). Impact of Carbapenem Resistance and Receipt of Active Antimicrobial Therapy on Clinical Outcomes of Acinetobacter baumannii Bloodstream Infections, Antimicrobial Agents and Chemotherapy, 55(10): 4844-4849.

Garnacho Montero, Guiterrez Pizayarra A, Díaz Martín A, Cisneros Herreros JM, Canoe ME, Gatoe E, Fernández Cuencaf CRAF, Vilag J, Martínez Martíneze L, Tomás Carmonah, Álvaro Pascualc MM, Bouh G, Pachón Diazb G, dan Rodrígue Ba˜noc J (2016). Infecciosas Clonali ad Mortalidad Acinetobacter baumannii en Pacientes Críticos: Epidemiología Molecular, Características Clínicas y Predictores de Mortalidadr. Enfermedades Infecciosas y Microbiología Clínica, 1460: 1-8.

Giedraitiene A, Vitkauskienė A, Naginienė R, dan Pavilonis A (2011). Antibiotic Resistance Mechanisms of Clinically Important Bacteria. Medicina (Kau-nas), 47(3): 137-146.

Kelly CM, Shahroni A (2016). Moving beyond Karnofsky and ECOG Performance Status Assessments with New Technologies. Journal of Oncology: 1-13.

Khaldi H, Maoualainine MF, Younous S, dan Soraa N (2017). Epidemiology of Acinetobacter baumannii Infection in a University Hospital. Journal of Pathology and Microbiology, 2(1): 1012-1018.

Kim SY, Jung JY, Kang YA, Lim JE, Kim EY, Lee SK, Park SC, Chung KS, et al. (2012). Risk Factors for Occurrence and 30-Day Mortality for Carbapenem Resistant Acinetobacter baumannii Bacteremia in an Intensive Care Unit. Journal of Korean Medical Science, 27: 939-947.

Lee SJ, Lindquist K, Segal MR, and Covinsky K E (2006). Development and validation of a prognostic index for 4 year mortality in older adults. Journal of the American Medical Association, 295(7): 801-808.

Lee SO, Kim NJ, Choi SH, Kim TH, Chung JW, Woo JW, Ryu J dan Kim JS (2004). Risk Factors for Acquisition of Imipenem Resistant Acinetobacter baumannii: a Case Control Study. Antimicrobial Agents and Chemotherapy, 48(1): 224-228.

Lei J, Han S, Wu W, dan Wang X, Xu J (2016). Extensively Drug Resistant Acinetobacter baumannii Outbreak Cross Transmitted in an Intensive Care Unit and Respiratory Intensive Care Unit. American Journal of Infection Control, 44: 1283-1287.

Lim C, Takahashi E, Hongsuwan M, Wuthiekanun V, Thamlikitkul V, Hinjoy S, Day NPJ, Peacock SJ, dan Limmathurotsakul D (2016). Epide miology and Burden of Multidrug Resistant Bacterial Infection in a Developing Country. Elife Science, 5: 1-18.

Lin M, dan Lan C (2014). Antimicrobial Resistance in Acinetobacter baumannii: From Bench to Bedside. World Journal of Clinical Cases, 2(12): 787-814.

Liu Q, Li W, Du X, Li W, Zhong T, Tang Y, Feng Y, Tao C, et al (2015). Risk and Prognostic Factors for Multidrug Resistant Acinetobacter Baumannii Complex Bacteremia: A Retrospective Study in a Tertiary Hospital of West China. PLoS ONE, 10(6): e0130701.

Mammina C, Palma DM, Bonura C, Aleo A, Fasciana T, Sodano C, Saporito MA, Verde MS, et al., (2012). Epidemio logy and clonality of carbapenemresistant Acinetobacter baumannii from an intensive care unit in Paler mo, Italy. BMC Research Notes, 5: 365-373.

Mody L, Gibson KE, HorcherA, Prenovost K, McNamara SE, Foxman B, Kaye KS, Bradley S. (2015). Prevalence of and Risk Factors for Multidrug Resistant Acinetobacter baumannii Colonization Among High Risk Nursing Home Residents. Infection Control Hospital Epidemiology, 36(10): 1155–1162.

Moeloek NF Penggunaan Antibiotik Bijak dan Rasional Kurangi Beban Penyakit Infeksi. Kementerian Kesehatan Republik Indonesia. (2015). antibiotik bijak dan rasional kurangi beban penyakit infeksi.html (diakses 10 Oktober 2106).

Peleg AY, Seifert H, dan Paterson DL (2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Cinical Microbiology Reviews, 21(3): 538–582.

Peus D, Newcomb N, dan Hofer S (2013). Appraisal of the Karnofsky Performance Status and Proposal of a Simple Algorithmic System for its Evaluation. BMC Medical Informatics and Decision Making, 13: 72-79.

Radji M, Fauziah S, Aribinuko N (2011). Antibiotic Sensitivity Pattern of Bacterial Pathogens in The Intensive Care Unit of Fatmawati Hospital, Indonesia. Asian Pacific Journal of Tropical Biomedicine, 1(1): 39-42.

Schechner V, Temkin E, Harbarth S, Carmeli Y, dan Schwaber MJ (2013). Epidemiological Interpretation of Studies Examining the Effect of Antibiotic Usage on Resistance. Clinical Microbiology Reviews, 26(2): 289–307.

Shorr AF, Zilberberg MD, Micek ST dan Kollef MH (2014). Predictors of hospital mortality among septic ICU patients with Acinetobacter spp. Bacteremia: a cohort study. BMC Infectious Diseases, 14: 572-579.

Taylor G, Garvel D, Matlow A, Embree J, LeSaux N, Johnston L, Suh K, John M, Embil E, Henderson E, Roth V, Wong A, dan the Canadian Nosocomial Infection Surveillance Program (2016). Assessing the Magnitude and Trends in Hospital Acquired Infections in Canadian Hospitals through Sequential Point Prevalence Surveys. Antimicrobial Resistance and Infection Control, 5(19): 1-7.

Tjoa E, Moeharjo LH, Rukmana A, dan Rohsiswatmo R (2013). Acinetobacter baumannii: Role in Blood Stream Infection in Neonatal Unit, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia. International Journal of Microbiology, 1-6.

Uwingabiye J, Frikh M, Lemnouer A, Bssaibis F, Belefquih B, Maleb A, Dahraoui S, Belyamani L, et al (2016). Acinetobacter Infections Prevalence and Frequency of The Antibiotics Resistance: Comparative Study of Intensive Care Units Versus Other Hospital Units. Pan African Medical Journal, 23: 191-201.

Verceles AC, Lechner EJ, Halpin D, dan Scharf SM (2013). The Association Between Comorbid Illness, Colonization Status, and Acute Hospitalization in Patients Receiving Prolonged Mechanical Ventilation. Respiration Care, 58(2): 250-256.

Vlek ALM, Cooper BS, Kypraios T, Cox A, Edgeworth JD dan Auguet OT (2013). Clustering of Antimicrobial Resistance Outbreaks Across Bacterial Species in the Intensive Care Unit. Clinical Infectious Diseases, 57(1): 65–76.

WHO (2016a). Antibiotics Resistance. (diakses 23 November 2016).

_____ (2016b). Antimicrobial Resistance. (diakses 30 November 2016).

Yang Y, Lee Y, Tsai W, Kuo S, Sun J, Yang C, Chen T, Lin J, et al (2013). Comparison between Bacteremia Caused by Carbapenem Resistant Acinetobacter baumannii and Acinetobacter nosocomialis. BMC Infectious Disease, 13: 311-318.

Ye JJ, Huang CT, Shie SS, Huang PY, Su LH, Chiu CH, Leu HS, Chiang PC (2010). Multidrug Resistant Acinetobacter baumannii: Risk Factors for Appearance of Imipenem Resistant Strains on Patients Formerly with Susceptible Strains. Plos One, 5(4): e9947.

Yoon YK, Yang KS, Lee SE, Kim HJ, Sohn JW, Kim MJ (2014). Effects of Group 1 versus Group 2 Carbapenems on the Susceptibility of Acinetobacter bau mannii to Carbapenems: A Before and After Intervention Study of Carbapenem Use Stewardship. PLoS ONE, 9(6): e99101.

Zowawi HM, Sartor AL, Sidjabat HE, Balkhy HH, Walsh TR, Al Johani SM, AlJindan RY, Alfaresi M, et al (2015). Molecular epidemiology of Carbapenem Resistant Acinetobacter baumannii isolates in the gulf cooperation council states: dominance of OXA 23 type producers. Journal of Clinical Microbiology, 53: 896-903.


  • There are currently no refbacks.